Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities researchers at Wedbush reduced their FY2019 earnings estimates for shares of Lexicon Pharmaceuticals in a research report issued on Thursday. Wedbush analyst L. Moussatos now expects that the biopharmaceutical company will post earnings per share of $0.66 for the year, down from their previous estimate of $0.74. Wedbush currently has a “Outperform” rating and a $38.00 target price on the stock. Wedbush also issued estimates for Lexicon Pharmaceuticals’ FY2020 earnings at $2.89 EPS.

Other analysts have also recently issued research reports about the company. Needham & Company LLC reissued a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, BidaskClub cut Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $28.50.

Shares of Lexicon Pharmaceuticals (NASDAQ LXRX) opened at $10.45 on Friday. Lexicon Pharmaceuticals has a 12-month low of $8.07 and a 12-month high of $18.00. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.07. The firm had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The business’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.35) earnings per share.

In related news, insider Lonnel Coats purchased 30,000 shares of Lexicon Pharmaceuticals stock in a transaction on Friday, September 15th. The stock was bought at an average price of $12.54 per share, with a total value of $376,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Public Equities L.P. Invus purchased 575,946 shares of Lexicon Pharmaceuticals stock in a transaction on Tuesday, November 14th. The stock was bought at an average cost of $9.64 per share, with a total value of $5,552,119.44. The disclosure for this purchase can be found here. Insiders acquired 945,353 shares of company stock valued at $9,304,953 in the last ninety days. Insiders own 5.77% of the company’s stock.

Several large investors have recently made changes to their positions in LXRX. Vanguard Group Inc. lifted its position in shares of Lexicon Pharmaceuticals by 16.3% in the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock worth $59,773,000 after buying an additional 585,222 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Lexicon Pharmaceuticals by 1.0% in the first quarter. Geode Capital Management LLC now owns 433,420 shares of the biopharmaceutical company’s stock worth $6,215,000 after buying an additional 4,141 shares during the last quarter. Morgan Stanley lifted its position in shares of Lexicon Pharmaceuticals by 22.7% in the first quarter. Morgan Stanley now owns 174,765 shares of the biopharmaceutical company’s stock worth $2,505,000 after buying an additional 32,276 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the first quarter worth about $3,750,000. Finally, State Street Corp lifted its position in shares of Lexicon Pharmaceuticals by 3.1% during the 1st quarter. State Street Corp now owns 1,641,167 shares of the biopharmaceutical company’s stock worth $23,536,000 after purchasing an additional 49,802 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Analysts Offer Predictions for Lexicon Pharmaceuticals, Inc.’s FY2019 Earnings (LXRX)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/analysts-offer-predictions-for-lexicon-pharmaceuticals-inc-s-fy2019-earnings-lxrx/1740501.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.